Descending control of pain
DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.
Projectdetails
Introduction
Pain is a large societal and health problem. Although often thought of as an invariant representation of active nociceptors, pain varies a lot under the influence of different affective states, sometimes with near complete analgesia. Such modulation of pain is thought to occur through a descending pathway originating in the brain and to be executed by Rostral Ventromedial Medulla (RVM) neurons that project to the spinal cord.
Challenges in Understanding Pain
Deciphering the complexity of the cell types involved and how they contribute to the descending control of pain has been challenging. However, recent advances in single-cell omics, computational biology, and advanced genetic technologies now open the door for unbiased system-wide insights.
Project Overview
DescendPain will uncover the power of the brain to control pain. We will classify RVM neuron types by single-cell RNA-sequencing and use scRNAseq-based stimulus-to-cell-type mapping to identify neuronal ensembles conferring analgesia and hyperalgesia during:
- Morphine
- Naloxone
- Stress
- Sleep-deprivation
- Exercise
Methodology
Using activity-based mouse genetics, we will reveal the full complexity of the combinations of neurons engaged and unravel their role in pain modulation. This will allow us to identify for the first time the cellular basis for how affective states modulate pain.
We will also use novel intersectional strategies for dual capturing of active neurons to determine how the descending RVM controls the transmission of pain in the ascending pathway of the spinal cord.
Chronic Pain Investigation
Finally, we will identify the memory substrate underlying chronic pain, providing evidence for the existence of RVM neuron ensembles of chronic pain and revealing underlying cellular and molecular mechanisms.
Conclusion
This project takes a new system-wide strategy in the pain field that should fundamentally change the view of pain. It will provide a cellular basis for how pain is continuously scaled by mental states and uncover mechanisms of chronic pain, which may provide strategies for designing effective pain therapies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-1-2023 |
Einddatum | 31-12-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- KAROLINSKA INSTITUTETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Uncovering the cortical cellular basis of specificity and chronicity of painThis project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief. | ERC Advanced... | € 2.468.700 | 2025 | Details |
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAINPersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients. | ERC Consolid... | € 1.618.278 | 2023 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disordersThis project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders. | ERC Advanced... | € 2.424.481 | 2024 | Details |
Neuronal control of fasciaThe NEUROFASCIA project aims to explore the fascia's role in brain-immune communication and its implications for pain and inflammation, using advanced techniques to characterize and modulate this tissue. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Uncovering the cortical cellular basis of specificity and chronicity of pain
This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders
This project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders.
Neuronal control of fascia
The NEUROFASCIA project aims to explore the fascia's role in brain-immune communication and its implications for pain and inflammation, using advanced techniques to characterize and modulate this tissue.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Oro Movement AIDit project onderzoekt de haalbaarheid van AI en machine learning voor het ontwikkelen van een instrument dat chronische pijn bij patiënten effectief kan monitoren en analyseren. | Mkb-innovati... | € 20.000 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Oro Movement AI
Dit project onderzoekt de haalbaarheid van AI en machine learning voor het ontwikkelen van een instrument dat chronische pijn bij patiënten effectief kan monitoren en analyseren.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.